ECSP14013165A - Cristal de compuesto heterocíclico fusionado - Google Patents

Cristal de compuesto heterocíclico fusionado

Info

Publication number
ECSP14013165A
ECSP14013165A ECSP14013165A ECSP14013165A EC SP14013165 A ECSP14013165 A EC SP14013165A EC SP14013165 A ECSP14013165 A EC SP14013165A EC SP14013165 A ECSP14013165 A EC SP14013165A
Authority
EC
Ecuador
Prior art keywords
fused heterocyclic
composite crystal
imidazo
pyridin
methyl
Prior art date
Application number
Other languages
English (en)
Inventor
Katsuhiko Yamamoto
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of ECSP14013165A publication Critical patent/ECSP14013165A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente invención se refiere a un cristal de 1-etil-7-metil-3-{4-[(3-metil-3H-imidazo[4,5-b]piridin-2-il)oxi]fenil}-1,3-dihidro-2H-imidazo[4,5-b]piridin-2-ona útil como un agente profiláctico o terapéutico para la esquizofrenia y similares, que muestra un patrón de difracción de polvo por rayos X con picos característicos en espaciamientos interplanares (d) de 13,59±0,2 y 6,76±0,2 Angstroms en la difracción de polvo por rayos X.
ECSP14013165 2011-06-22 2014-01-22 Cristal de compuesto heterocíclico fusionado ECSP14013165A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2011138920 2011-06-22

Publications (1)

Publication Number Publication Date
ECSP14013165A true ECSP14013165A (es) 2014-02-28

Family

ID=46551819

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP14013165 ECSP14013165A (es) 2011-06-22 2014-01-22 Cristal de compuesto heterocíclico fusionado

Country Status (26)

Country Link
US (1) US9512118B2 (es)
EP (1) EP2723738B1 (es)
JP (1) JP6025757B2 (es)
KR (1) KR20140040777A (es)
CN (1) CN103608348B (es)
AR (1) AR087004A1 (es)
AU (1) AU2012274292B2 (es)
BR (1) BR112013032052A2 (es)
CA (1) CA2839825C (es)
CL (1) CL2013003632A1 (es)
CO (1) CO6862150A2 (es)
CR (1) CR20140033A (es)
DO (1) DOP2013000311A (es)
EA (1) EA026137B1 (es)
EC (1) ECSP14013165A (es)
GE (1) GEP20166475B (es)
MA (1) MA35274B1 (es)
MX (1) MX342990B (es)
MY (1) MY163483A (es)
PE (1) PE20141030A1 (es)
TN (1) TN2013000510A1 (es)
TW (1) TWI570122B (es)
UA (1) UA112082C2 (es)
UY (1) UY34150A (es)
WO (1) WO2012176934A1 (es)
ZA (1) ZA201309611B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5973990B2 (ja) * 2011-03-16 2016-08-23 武田薬品工業株式会社 縮合複素環化合物
US10851076B2 (en) 2017-08-10 2020-12-01 Pratt Bethers Method for purifying crystals using solvent vapors
US10308626B1 (en) 2018-07-02 2019-06-04 Pratt Bethers Crystal purification in a glass or metal container
US10960322B2 (en) 2018-07-02 2021-03-30 Pratt Bethers Apparatus for purifying crystals using solvent vapors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597826A (en) * 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
WO2006038111A1 (en) * 2004-10-07 2006-04-13 Pfizer Products Inc. Benzoimidazole derivatives useful as antiproliferative agents
WO2007026664A1 (ja) 2005-08-30 2007-03-08 Asahi Kasei Pharma Corporation スルホンアミド化合物
FI20055498A0 (fi) 2005-09-16 2005-09-16 Biotie Therapies Corp Sulfonamidijohdannaisia
US7618982B2 (en) 2005-12-19 2009-11-17 Nerviano Medical Sciences S.R.L. Heteroarylpyrrolopyridinones active as kinase inhibitors
CA2636873A1 (en) * 2006-02-15 2007-08-23 Sanofi-Aventis Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
US20080090834A1 (en) * 2006-07-06 2008-04-17 Pfizer Inc Selective azole pde10a inhibitor compounds
KR101524817B1 (ko) 2007-04-18 2015-06-01 깃세이 야쿠힌 고교 가부시키가이샤 질소 함유 축합환 유도체, 그것을 함유하는 의약 조성물 및 그 의약 용도
EP2276747A1 (en) 2008-03-11 2011-01-26 Cellzome Limited Sulfonamides as zap-70 inhibitors
TW201030001A (en) 2008-11-14 2010-08-16 Amgen Inc Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors
TWI396689B (zh) 2008-11-14 2013-05-21 Amgen Inc 作為磷酸二酯酶10抑制劑之吡衍生物
WO2010126002A1 (ja) 2009-04-28 2010-11-04 塩野義製薬株式会社 ヘテロ環スルホンアミド化合物を含有する医薬
EP2585462B1 (en) * 2010-06-24 2020-02-26 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds as phosphodiesterases (pdes) inhibitors
US9029536B2 (en) 2010-08-04 2015-05-12 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
US9150588B2 (en) 2010-08-10 2015-10-06 Takeda Pharmaceutical Company Limited Substituted pyridazin-4(1H)-ones as phosphodiesterase 10A inhibitors
JP5973990B2 (ja) 2011-03-16 2016-08-23 武田薬品工業株式会社 縮合複素環化合物

Also Published As

Publication number Publication date
MX342990B (es) 2016-10-20
UY34150A (es) 2013-01-31
CO6862150A2 (es) 2014-02-10
EP2723738A1 (en) 2014-04-30
MY163483A (en) 2017-09-15
WO2012176934A1 (en) 2012-12-27
CR20140033A (es) 2014-03-12
AR087004A1 (es) 2014-02-05
MA35274B1 (fr) 2014-07-03
JP6025757B2 (ja) 2016-11-16
CL2013003632A1 (es) 2014-06-06
TN2013000510A1 (en) 2015-03-30
CN103608348B (zh) 2016-03-30
CA2839825A1 (en) 2012-12-27
CA2839825C (en) 2019-04-09
UA112082C2 (uk) 2016-07-25
EP2723738B1 (en) 2018-03-14
JP2014516918A (ja) 2014-07-17
TW201313709A (zh) 2013-04-01
NZ618944A (en) 2015-08-28
ZA201309611B (en) 2014-08-27
PE20141030A1 (es) 2014-08-29
CN103608348A (zh) 2014-02-26
AU2012274292B2 (en) 2016-10-27
GEP20166475B (en) 2016-05-10
MX2013015354A (es) 2014-02-11
TWI570122B (zh) 2017-02-11
BR112013032052A2 (pt) 2016-12-13
US20140113932A1 (en) 2014-04-24
EA026137B1 (ru) 2017-03-31
DOP2013000311A (es) 2014-02-28
US9512118B2 (en) 2016-12-06
EA201490092A1 (ru) 2014-05-30
AU2012274292A1 (en) 2014-01-16
KR20140040777A (ko) 2014-04-03

Similar Documents

Publication Publication Date Title
HRP20182007T1 (hr) Derivati 3-okso-2,3,5,8-tetrahidro-[1,2,4]triazolo[4,3-a]pirimidina za liječenje respiratornih bolesti
PH12015500988B1 (en) Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
IL229193A0 (en) The history of pyridine-2--(h1) and its effectiveness as drugs for the treatment of myeloproliferative disorders, graft rejection, and infectious and immune-mediated diseases
BR112014032338A2 (pt) cristais de sal
ZA201307783B (en) Tri-and tetracylic pyrazolo[3,4-b]pyridine compounds as antineoplastic agent
ECSP14013165A (es) Cristal de compuesto heterocíclico fusionado
SG11201406185WA (en) Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases
NZ607527A (en) Fused heteroaryls and their uses
IL236067B (en) Preparations of galacto-rhamnogalacturonate for the treatment of diseases associated with high inducible nitric oxide synthase
IL236480B (en) A process for the preparation of n-oxides of 5-(1-alkylthio)alkyl-pyridine substituted in position 2
PL393991A1 (pl) Sposób wytwarzania kompozytowego katalizatora do niskotemperaturowego rozkładu podtlenku azotu
SG10201600776VA (en) Method of miniature two axes four-wheel drive control with precision magnetic encoder design
SG2012080370A (en) Method of miniature two axes four-wheel drive control with precision magnetic encoder design
IL236662A0 (en) Antitumor preparation containing urea compound 1-(6-{[6-(4-fluorophenyl) [4,2,1]triazolo [3,4-b]pyridazin-3-yl]sulfanyl}-3,1-benzothiazole- 2-yl]-3-(2-morpholine-4-ylethyl)
CU24344B1 (es) Imidazo[1,2-a]piridincarboxamidas aminosustituidas
UA72222U (ru) Способ лечения геликобактер-ассоциированной язвенной болезни у детей
NZ623063A (en) Antibacterial compounds and methods for use
PL394218A1 (pl) Nowe zwiazki, pochodne pirydo[2",3":5', 6']pirazyno[2', 3' : 5,6][1,4]ditiino[2,3-b]chinoksaliny oraz sposób ich wytwarzania